<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5832">
  <stage>Registered</stage>
  <submitdate>10/06/2015</submitdate>
  <approvaldate>10/06/2015</approvaldate>
  <nctid>NCT02470585</nctid>
  <trial_identification>
    <studytitle>Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</studytitle>
    <scientifictitle>A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-005070-11</secondaryid>
    <secondaryid>M13-694</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Ovarian Neoplasm</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Placebo
Treatment: drugs - Veliparib
Treatment: drugs - Veliparib
Treatment: drugs - Carboplatin
Treatment: drugs - Paclitaxel

Placebo Comparator: Arm 1 - Carboplatin/paclitaxel plus placebo for six 21-day cycles followed by placebo maintenance therapy for up to 30 additional 21-day cycles

Experimental: Arm 2 - Carboplatin/paclitaxel plus veliparib for six 21-day cycles followed by placebo maintenance therapy for up to 30 additional 21-day cycles

Experimental: Arm 3 - Carboplatin/paclitaxel plus veliparib for six 21-day cycles followed by veliparib maintenance therapy for up to 30 additional 21-day cycles


Other interventions: Placebo
Capsule

Treatment: drugs: Veliparib
Capsule

Treatment: drugs: Veliparib
Capsule

Treatment: drugs: Carboplatin
Intravenous infusion

Treatment: drugs: Paclitaxel
Intravenous infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-Free survival (PFS) - Defined as the number of days from the date that the subject was randomized to the date the subject experiences an event of disease progression or to the date of death (all causes of mortality) if disease progression is not reached.</outcome>
      <timepoint>Approximately 3 years from first dose of study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - Time to death for a given subject will be defined as the number of days from the date that the subject was randomized to the date of the subject's death.</outcome>
      <timepoint>Approximately 6 years from first dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Related Symptom (DRS) scores</outcome>
      <timepoint>Up to 2 years or disease progression from randomization, whichever is later</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO)
             Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma,
             with the appropriate tissue available for histologic evaluation.

          2. High-grade serous adenocarcinoma

          3. Willing to undergo testing for gBRCA.

          4. Adequate hematologic, renal, and hepatic function.

          5. Neuropathy (sensory and motor) less than or equal to Grade 1.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          7. Participants who undergo primary cytoreductive surgery must be entered between 1 and
             12 weeks after surgery. Participants undergoing interval surgery must have a tumor
             sample confirming the histological diagnosis prior to enrollment.

          8. Participants with measurable disease or non-measurable disease are eligible.
             Participants may or may not have cancer-related symptoms.

          9. Participant has one of the following available for PD analyses including somatic BRCA
             testing: Archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue; or
             tumor tissue biopsy collected prior to Cycle 1 Day 1.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed
             epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous
             adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or
             malignant Brenner's tumor.

          2. Participants with synchronous primary endometrial cancer, or a past history of
             endometrial cancer unless all of the following conditions are met: endometrial cancer
             stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated
             subtypes including serous, clear cell, or other FIGO grade 3 lesions.

          3. Participants with any evidence of other invasive malignancy being present within the
             last 3 years (with the exception of non-melanoma skin cancer). Participants are also
             excluded if their previous cancer treatment contraindicates this protocol's therapy.

          4. Received prior radiotherapy to any portion of the abdominal cavity or pelvis.

          5. Received prior chemotherapy for any abdominal or pelvic tumor.

          6. Clinically significant uncontrolled condition(s).

          7. Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant
             Tartrazine (also known as FD&amp;C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also
             known as FD&amp;C Yellow 6 or E110) or known contraindications to any study supplied drug.

          8. History or evidence upon physical examination of central nervous system (CNS) disease,
             including primary brain tumor, any brain metastases, or history of cerebrovascular
             accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day
             1.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>16/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>4/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital /ID# 150071 - Adelaide</hospital>
    <hospital>Chris O'Brien Lifehouse /ID# 145298 - Camperdown</hospital>
    <hospital>Coffs Harbour Health Campus /ID# 145132 - Coffs Harbour</hospital>
    <hospital>The Townsville Hospital and Health Services /ID# 149163 - Douglas</hospital>
    <hospital>Monash Halth /ID# 145297 - East Bentleigh</hospital>
    <hospital>Barwon Health, University Hospital of Geelong /ID# 147743 - Geelong</hospital>
    <hospital>Central Coast Cancer Centre /ID# 145299 - Gosford</hospital>
    <hospital>Royal Brisbane and Womens Hospital /ID# 145135 - Herston QLD</hospital>
    <hospital>St. George Hospital /ID# 145138 - Kogarah</hospital>
    <hospital>Cabrini Health /ID# 145142 - Malvern</hospital>
    <hospital>Sir Charles Gairdner Hospital /ID# 145140 - Nederlands, Perth</hospital>
    <hospital>Newcastle Private Hospital /ID# 145834 - New Lambton Heights</hospital>
    <hospital>Royal Womens Hospital /ID# 145136 - Parkville</hospital>
    <hospital>The Prince of Wales Hospital /ID# 145134 - Randwick</hospital>
    <hospital>Icon Cancer Centre /ID# 148208 - South Brisbane</hospital>
    <hospital>Mater Health Hospital /ID# 145682 - South Brisbane</hospital>
    <hospital>Western Health Sunshine Hospital /ID# 145296 - St. Albans</hospital>
    <hospital>Northern Cancer Institute /ID# 145681 - St. Leonards</hospital>
    <hospital>St. John of God Subiaco Hospital /ID# 147742 - Subiaco</hospital>
    <hospital>Calvary Mater Newcastle /ID# 145139 - Waratah</hospital>
    <hospital>Westmead Hospital /ID# 145137 - Westmead</hospital>
    <hospital>Southern Medical Day Care Center /ID# 145133 - Wollongong</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2450 - Coffs Harbour</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>2250 - Gosford</postcode>
    <postcode>4029 - Herston QLD</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>6009 - Nederlands, Perth</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3021 - St. Albans</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>6008 - Subiaco</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2500 - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alaska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Provincia de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario, Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Barretos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belo Horizonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Itajai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre/RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herning</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Vejle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehevot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kashiwa-shi, Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kawasaki-shi, Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kawasaki-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kumamoto-shi, Kumamoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kure-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kurume-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Matsuyama-shi, Ehime</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Mie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Morioka-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagaizumi-cho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagoya-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka sayama-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sapporo-shi, Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sapporo-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sendai-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Yamagata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Great Yarmouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich, Norfolk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Gynecologic Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australia New Zealand Gynaecological Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib in
      women with previously untreated, Stage III or IV, high-grade serous, epithelial ovarian,
      fallopian tube, or primary peritoneal cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02470585</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Minh Dinh, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>